Blog
RSS FeedPosted by Michael Wonder on 26 Feb 2020
UK NICE to announce decision on Vertex’s therapy Trikafta in December
26 February 2020 - NICE is currently in the process of evaluating Vertex Pharmaceuticals’ triple combination therapy — known as ...
Posted by Michael Wonder on 26 Feb 2020
Polivy struck by NICE ‘no’
26 February 2020 - The National Institute for Health and Care Excellence has announced that it does not recommend Polivy ...
Posted by Michael Wonder on 22 Feb 2020
UK deal over inclisiran
18 February 2020 - Government’s public enthusiasm looks premature given the lack of available data ...
Posted by Michael Wonder on 22 Feb 2020
Health ministers condemn Novartis lottery for Zolgensma, the world’s most expensive drug
12 February 2020 - Novartis has held the first draw to choose four babies who will receive its one-shot treatment ...
Posted by Michael Wonder on 12 Feb 2020
Researchers wanted to study the public’s views of health-related quality of life
12 February 2020 - Applications close on Wednesday 4 March 2020 ...
Posted by Michael Wonder on 12 Feb 2020
NICE refuses Keytruda, Inlyta cancer combo
12 February 2020 - NICE has released a draft guidance rejecting MSD’s Keytruda (pembrolizumab) when used in combo with Pfizer’s ...
Posted by Michael Wonder on 05 Feb 2020
NICE plans to widen the net for data it uses in guidance
5 February 2020 - UK cost-effectiveness body NICE has said it intends to use a broader range of data and ...
Posted by Michael Wonder on 04 Feb 2020
Broader types of data to be used in development of NICE guidance
4 February 2020 - An expanded evidence base could allow NICE to address evidence gaps and enhance reviews of the impact ...
Posted by Michael Wonder on 04 Feb 2020
Appeal panel rules that NICE needs to request evidence for erenumab effectiveness in subgroup of people with chronic migraine
4 February 2020 - NICE has today published the outcome of the appeal against its final draft guidance on erenumab (Aimovig; ...
Posted by Michael Wonder on 03 Feb 2020
Rinvoq NICE approval could benefit 54,000 people
3 February 2020 - The National Institute for Health and Care Excellence has announced a new draft guidance recommending Abbvie’s ...
Posted by Michael Wonder on 30 Jan 2020
Brexit D-Day
31 January 2020 - After more than three years of Brexit talks, deals and political wrangling, the United Kingdom will officially ...
Posted by Michael Wonder on 30 Jan 2020
Survey finds 87 percent of pharmacists concerned about medicine supply post-Brexit
29 January 2020 - New findings reveal that the majority of pharmacists are worried about the supply of medicine to the ...
Posted by Michael Wonder on 30 Jan 2020
NICE publishes updated principles
30 January 2020 - NICE has today, 30 January 2020, published a simple guide to the way we develop our guidance ...
Posted by Michael Wonder on 29 Jan 2020
Cancer patients facing delays in getting ‘innovative’ drugs
29 January 2020 - A new analysis report has found that most innovative cancer drugs face delays in reaching patients. ...
Posted by Michael Wonder on 27 Jan 2020
NICE rejections continue, hitting Novo’s Saxenda next
27 January 2020 - Continuing a string of NICE rejections, Novo Nordisk’s weight management drug Saxenda (liraglutide) is next to ...